PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | March 2013 |
| End Date: | January 2016 |
The goals of this study are two fold: 1) To learn whether a personalized patient health goal
and reminder tool helps patients to learn more about their condition and to make changes in
behavior and medication taking to reduce the risk of another heart attack. 2) To examine a
blood sample to learn how patients are responding to their medications. The study team will
enroll approximately 220 patients in the hospital recovering from a heart attack. Half of
the patients will receive the educational tools and a copy will be sent to their outpatient
provider.
and reminder tool helps patients to learn more about their condition and to make changes in
behavior and medication taking to reduce the risk of another heart attack. 2) To examine a
blood sample to learn how patients are responding to their medications. The study team will
enroll approximately 220 patients in the hospital recovering from a heart attack. Half of
the patients will receive the educational tools and a copy will be sent to their outpatient
provider.
The goals of this study are two fold: 1) To evaluate the impact of a personalized patient
health goal education and reminder tool on patient adherence to evidence based therapies and
subsequent cardiovascular risk factor modification after acute myocardial infarction (AMI);
2) To assess age-related heterogeneity in antiplatelet response among AMI patients. This is
a prospective study of ~220 AMI patients, with at least half over age 65 years. Patients
will be surveyed with questionnaires (at baseline and 6 months post discharge) and
biomarkers (baseline only) to assess the status of their physical function, depression,
nutrition, inflammation, and response to antiplatelet therapies. Patients will also be
administered a walking test and a grip strength test at baseline. About 1 week after
hospital discharge, and again about 3 months after hospital discharge, about half of the
patients and their outpatient providers will receive the personalized post-AMI health goal
education and reminder tool on patient adherence to evidence-based secondary prevention
therapies. Data will be analyzed in aggregate using descriptive statistics. The primary
endpoint of interest is a composite measure of adherence at six months to secondary
prevention therapies described as the sum of measures received divided by the sum of
available opportunities. The secondary endpoint will be analyzed to describe platelet
response profiles as a function of age. The study team anticipates the risks for this study
to be minimal, since the patient does not receive any investigational therapies.
health goal education and reminder tool on patient adherence to evidence based therapies and
subsequent cardiovascular risk factor modification after acute myocardial infarction (AMI);
2) To assess age-related heterogeneity in antiplatelet response among AMI patients. This is
a prospective study of ~220 AMI patients, with at least half over age 65 years. Patients
will be surveyed with questionnaires (at baseline and 6 months post discharge) and
biomarkers (baseline only) to assess the status of their physical function, depression,
nutrition, inflammation, and response to antiplatelet therapies. Patients will also be
administered a walking test and a grip strength test at baseline. About 1 week after
hospital discharge, and again about 3 months after hospital discharge, about half of the
patients and their outpatient providers will receive the personalized post-AMI health goal
education and reminder tool on patient adherence to evidence-based secondary prevention
therapies. Data will be analyzed in aggregate using descriptive statistics. The primary
endpoint of interest is a composite measure of adherence at six months to secondary
prevention therapies described as the sum of measures received divided by the sum of
available opportunities. The secondary endpoint will be analyzed to describe platelet
response profiles as a function of age. The study team anticipates the risks for this study
to be minimal, since the patient does not receive any investigational therapies.
Inclusion Criteria:
1. Patients with either ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI) who are
on antiplatelet therapy at the time of enrollment.
2. English language literacy and
3. Able to provide written informed consent.
Exclusion Criteria:
1. Patients less than 18 years of age.
2. Patients who are unable or unwilling to comply with the protocol or not expected to
complete the study period, including its follow-up requirements
3. Life expectancy less than 6 months or discharged on hospice care.
4. Patients without at least 1 scheduled outpatient follow-up visit inside the Duke
University Affiliated Physicians network.
5. Patients who receive a coronary artery bypass grafting (CABG) during the eligible
enrollment hospitalization.
6. Active chronic inflammatory conditions (e.g., inflammatory bowel disease, lupus,
rheumatoid arthritis)
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
